A corporate venture capital arm of a global generic manufacturer headquartered in Western Europe can invest up to $5m in a round. They will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. They are open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based venture capital firm had its beginnings as an incubator, providing seed funding to very early-stage companies for the first two years. Since then, the firm has also branched into a venture arm that expanded the investment focus to Series A financing rounds. The firm is actively seeking investments and will allocate around $500K – 2.5 M, with preferred financing structures being equity and convertible preferred equity. Although the firm has invested in companies outside the USA, the firm focuses its investments on USA-based companies.

In the life sciences space, the firm is primarily interested in healthcare IT/digital health technologies and services as well as medical devices and diagnostic tools that have a tech-enabled component. The firm is open to devices of all FDA regulatory pathways including 510k and PMA. Products that have not begun clinical trials will most likely be considered too early, so these devices should at least be undergoing clinical trials. The firm is not interested in companies in the therapeutics sector.

The firm seeks to work with privately owned companies with an experienced management team that is dedicated full-time. CEOs with experience founding successful start-up companies is a strong plus. The firm can act as either a lead or co-investor in financing rounds, and will generally seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A thesis-driven earliest stage firm looks to lead investments in early-stage companies that are pre-seed. The firm is currently investing out of their second fund of USD 67 million. The firm primarily participates in equity investments including SAFEs but will consider other types of capital structures as requested by a founder. The firm invests largely in companies based in the United States and Canada but will also consider Europe and Latin America.

The firm is primarily interested in investing in companies in the digital health, diagnostics, and medical technology sectors with a focus in platform technologies. The firm will not consider investments in medical device companies. However, the firm will consider therapeutics with a platform technology component. The firm will only invest in technologies that are still pre-clinical and in development. The firm is disease agnostic and will consider companies across all indications including orphan diseases.

The firm will work with experienced and inexperienced management teams. The firm looks to invest in founders who are dedicated to their technology and their company. The firm is an active investor and will take an observer board seat as determined on a case-by-case basis. The firm prefers to act as a lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A single family office representing USA-based family interests is very flexible in terms of investment size, but are generally looking to invest a minimum of $.5 million per round, depending upon size of round and estimated capital call. The firm prefers A round and later stage companies. Pre-A interest depends upon technology stage. Currently, the firm is investing only in companies based in North America.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. Currently, of particular interest are optical or sound-based technologies, devices that supplant drug use, orthopedics, gene/nucleic acid-based therapies, immuno-oncology and therapies correcting or treating loss of senses.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor. The firm is looking for companies that have already raised seed financing and have received allowance of claims by the USPTO.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in the USA. With about USD 600 million in assets under management, the firm looks to participate in pre-seed to pre-IPO funding. The firm launched a second fund expects to complete fundraising by Q2 2023. The firm will typically make between 15 and 20 new investments per year and will typically make follow up investments in existing portfolio companies. Typical investments range between USD 100 thousand and USD 30 million. The firm will utilize various capital structures as determined on a case-by-case basis including equity investments debt, convertible loans, and SAFEs. The firm invests primarily in companies in the Boston area.

The firm will make investments across all modalities within the medical devices, diagnostics, and digital health sectors. The firm has made and will consider investments in therapeutics as well but prefers to focus on platform technologies. The firm will invest in therapeutics that are pre-NDA as well as medical and diagnostic technology that is in development and clinical. The firm will invest in all classes of medical devices including Class II (510k) and Class III (PMA). The firm is disease agnostic and will consider companies across all indications.

The firm will work with both experienced and inexperienced management teams but tends to avoid management teams led by a journeyman CEO. The firm will participate as a lead investor, co-investor, and follow-on investor. The firm will take an active board seat if acting as the lead investor but tends to take a board observer seat if acting as a co-investor. The firm will not take any board seat if acting as a follow-on investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture capital firm is focused on early stage investment to support founders and their teams advance healthcare solutions. The team originated at a medical device company that has worked with researchers and physicians for more than 50 years to develop more effective tools. The firm makes initial investments in pre-seed and seed rounds (with reserve to follow in A rounds) as a dedicated partner working closely with startups to advance technologies and build companies. Initial investment ranges from $100k-$1M. The firm has a global presence and is open to early-stage companies from around the world.

The firm’s investment focus is digital solutions to improving healthcare. The firm is open to investing in companies across all stages of development.

The firm has no strict requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

One of the earliest venture capital funds active in Greater China is the proprietary venture capital and private equity arm of a world’s leading asset management organization with operations around the globe. Since inception, the firm has developed a broad footprint across Asia, with offices in Beijing, Shanghai, Hong Kong, Delhi, Mumbai and Tokyo. The firm specializes in green-field, early and growth stage investments.

Within life sciences, the firm works on a wide range of technology sectors including therapeutics, medical devices, diagnostics, biotech R&D services, healthcare IT, and healthcare services. The firm is very opportunistic in terms of subsectors and indications but historically has been active in biosimilars and biotech R&D. The firm evaluates technologies based on two main criteria: meaningful impact on human health; bold and innovative ideas. The firm has no specific preference in the investment stage. However, the firm generally invests in earlier stage for therapeutics and R&D and later stage for medical devices, but seeds have been done with exceptional founding teams.

The firm is seeking companies with a strong and experienced management team. The firm is flexible when it comes to post-investment board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.